 <h1>Halcion Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>triazolam</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about triazolam. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Halcion.</p><h2>In Summary</h2><p><b>More frequent side effects include:</b> dizziness, insomnia, rebound insomnia, headache, and irritability.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to triazolam: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients with inadequate alternative treatment options. Limit dosage and duration to the minimum required and follow patients for signs and symptoms of respiratory depression and sedation.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, triazolam (the active ingredient contained in Halcion) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking triazolam:</p><p>
<i>Less common</i>
</p><ul>
<li>Shakiness and unsteady walk</li>
<li>unsteadiness, trembling, or other problems with muscle control or coordination</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Being forgetful</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>continuing ringing or buzzing or other unexplained noise in the ears</li>
<li>discouragement</li>
<li>false or unusual sense of well-being</li>
<li>fast, pounding, or irregular heartbeat or pulse</li>
<li>feeling sad or empty</li>
<li>hearing loss</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>loss of interest or pleasure</li>
<li>nightmares</li>
<li>tiredness</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Actions that are out of control</li>
<li>aggressiveness</li>
<li>anxiety</li>
<li>changes in patterns and rhythms of speech</li>
<li>chest pain</li>
<li>chills</li>
<li>clay-colored stools</li>
<li>confusion about identity, place, and time</li>
<li>dark urine</li>
<li>decrease in frequency of urination</li>
<li>decrease in urine volume</li>
<li>difficulty in passing urine (dribbling)</li>
<li>dizziness</li>
<li>drowsiness</li>
<li>dry mouth</li>
<li>environment seems unreal</li>
<li>fainting</li>
<li>falling</li>
<li>false beliefs that cannot be changed by facts</li>
<li>feeling of unreality</li>
<li>fever</li>
<li>headache</li>
<li>hyperventilation</li>
<li>inability to move the eyes</li>
<li>increased blinking or spasms of the eyelid</li>
<li>increased muscle spasm</li>
<li>irregular heartbeat</li>
<li>loss of bladder control</li>
<li>loss of memory</li>
<li>nausea</li>
<li>nervousness</li>
<li>painful urination</li>
<li>problems with memory</li>
<li>rash</li>
<li>relaxed and calm feeling</li>
<li>restlessness</li>
<li>seeing, hearing, or feeling things that are not there</li>
<li>sense of detachment from self or body</li>
<li>sleep walking</li>
<li>sleepiness</li>
<li>slurred speech</li>
<li>sticking out of tongue</li>
<li>stomach pain</li>
<li>talking, feeling, and acting with excitement</li>
<li>trouble breathing, speaking, or swallowing</li>
<li>uncontrolled twisting movements of the neck, trunk, arms, or legs</li>
<li>unpleasant breath odor</li>
<li>unusual excitement, nervousness, restlessness, or irritability</li>
<li>unusual facial expressions</li>
<li>unusual tiredness or weakness</li>
<li>vomiting of blood</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of triazolam may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Lightheadedness</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Blistering, crusting, irritation, itching, or reddening of the skin</li>
<li>change in taste, or bad, unusual, or unpleasant (after) taste</li>
<li>change in vision</li>
<li>cracked, dry, or scaly skin</li>
<li>cramps</li>
<li>diarrhea</li>
<li>difficulty having a bowel movement</li>
<li>dry mouth</li>
<li>swelling</li>
<li>weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Decreased interest in sexual intercourse</li>
<li>inability to have or keep an erection</li>
<li>increase in sexual ability, desire, drive, or performance</li>
<li>increase interest in sexual intercourse</li>
<li>itching skin</li>
<li>loss in sexual ability, desire, drive, or performance</li>
<li>menstrual changes</li>
<li>redness, swelling, or soreness of the tongue</li>
<li>swelling or inflammation of the mouth</li>
<li>weight loss</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to triazolam: oral tablet</i></p><h3>General</h3><p>The most commonly reported side effects included drowsiness/sedation, dizziness/lightheadedness, headache, and ataxia.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Sedation (up to 19.4%), drowsiness (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Anterograde amnesia with appropriate/inappropriate behavior, ataxia, concentration difficulty, coordination disorders/impaired coordination, dizziness, headache, impaired equilibrium, lethargy, lightheadedness, memory impairment</p>
<p><b>Rare</b> (0.01% to 0.1%): Dysesthesia, paresthesia, taste alterations</p>
<p><b>Frequency not reported</b>: Amnestic symptoms, clouding of consciousness/altered state of consciousness, dysarthria, dystonia, grogginess, slurred speech, somnambulism, somnolence, syncope<sup>[Ref]</sup></p><p>Complex behaviors, such as "sleep-driving", other behaviors such as preparing and eating food, making phone calls, or having sex, with amnesia for these events, have been reported at therapeutic doses with this medicine.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): WBC/high power field (HPF) in urinalysis (up to 11.3%)</p>
<p><b>Common</b> (1% to 10%): Albuminuria, red blood cells/HPF in urinalysis</p>
<p><b>Frequency not reported</b>: Bladder trouble, incontinence, menstrual irregularities, urinary retention<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Low eosinophil count (up to 10.2%)</p>
<p><b>Common</b> (1% to 10%): High eosinophil count, low monocyte count, low/high basophil count, low/high lymphocyte count, low/high neutrophil count, low/high WBC count</p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): High bilirubin, increased alkaline phosphatase, low/high creatinine</p>
<p><b>Frequency not reported</b>: Anorexia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Rebound insomnia (a worsening of sleep following cessation of therapy) has been observed and has sometimes been reported to occur in association with increased daytime anxiety.</p>
<p></p>
<p>Withdrawal symptoms have included agitation, restlessness, anxiety, insomnia, psychosis, delirium, convulsions, tremor, abdominal cramps, blurred vision, vomiting, and sweating.</p>
<p></p>
<p>Worsening of insomnia, depression, or the emergence of new thinking or behavior abnormalities, including suicidal thinking, have emerged during treatment with sedative-hypnotic drugs, including this drug.  The frequency and extent to which this drug is associated with adverse behavioral effects is controversial.</p>
<p></p>
<p>One study based on the postmarketing surveillance Spontaneous Reporting System of the FDA has suggested that adverse behavioral reactions have been reported 22 to 99 times more frequently in association with triazolam (the active ingredient contained in Halcion) therapy than with temazepam therapy for insomnia.  An increased frequency of adverse behavioral effects was noted to occur most frequently in elderly patients and at higher doses of this drug.  The methodology of this study, however, has been questioned on the grounds that spontaneous reports of adverse effects do not necessarily correlate with the incidence of adverse effects.</p>
<p></p>
<p>Other studies and reports have concluded that little evidence exists to support the contention that this drug is associated with a greater risk of adverse behavioral effects than other benzodiazepines (including temazepam).<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Anxiety, nervousness</p>
<p><b>Uncommon</b> (0.1% to 1%): Confusional states, depression, euphoria</p>
<p><b>Rare</b> (0.01% to 0.1%): Dreaming, insomnia, nightmares</p>
<p><b>Frequency not reported</b>: Abnormal behavior, abnormal dreams, abuse, acute rage, addiction, aggressiveness/aggression, agitation, agitational state, bizarre behavior, changes in libido, delusions, depersonalization, derealization, disorientation, disorientation in time/place, excitation, hallucinations, inappropriate behavior, irritability, libido disorder, mania, other adverse behavioral effects, paranoia, restlessness, sleep disorder/sleep disturbances, stimulation<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomiting</p>
<p><b>Rare</b> (0.01% to 0.1%): Constipation, diarrhea, dry mouth</p>
<p><b>Frequency not reported</b>: Abdominal distress, burning tongue, glossitis, stomatitis, tongue discomfort<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Tiredness</p>
<p><b>Uncommon</b> (0.1% to 1%): Pain</p>
<p><b>Rare</b> (0.01% to 0.1%): Tinnitus, weakness</p>
<p><b>Frequency not reported</b>: Falling, fatigue, paradoxical reactions<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): High AST levels</p>
<p><b>Rare</b> (0.01% to 0.1%): Death (from hepatic failure)</p>
<p><b>Frequency not reported</b>: Jaundice<sup>[Ref]</sup></p><p>Death from hepatic failure has been reported in a patient also receiving diuretic drugs.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Pruritus, skin rash</p>
<p><b>Rare</b> (0.01% to 0.1%): Dermatitis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Palpitations, tachycardia</p>
<p><b>Frequency not reported</b>: Chest pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Hiccups</p>
<p><b>Rare</b> (0.01% to 0.1%): Congestion<sup>[Ref]</sup></p><p>One study of patients with obstructive sleep apnea has suggested that this drug may increase the maximum apnea duration and lower the minimum oxygen saturation of apneic patients.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Cramps</p>
<p><b>Frequency not reported</b>: Aching limbs, backache, increased muscle spasticity<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Visual disturbances</p>
<p><b>Frequency not reported</b>: Blepharitis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (0.01% to 0.1%): Allergy</p>
<p><b>Postmarketing reports</b>: Anaphylactic shock, anaphylactoid reaction, allergic edema, angioneurotic edema, hypersensitivity reaction<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_3">3. Rothschild AJ "Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: a review of the literature." J Clin Psychiatry 53 (1992): 69-79</p><p id="ref_4">4. Morris HH, 3d  Estes ML "Traveler's amnesia. Transient global amnesia secondary to triazolam." JAMA 258 (1987): 945-6</p><p id="ref_5">5. Patterson WM "Triazolam withdrawal." J Clin Psychiatry 49 (1988): 369</p><p id="ref_6">6. Andreadis NA, Schirmer RG "Use of spontaneous reporting system data." Arch Intern Med 152 (1992): 1527-9</p><p id="ref_7">7. Wysowski DK, Barash D "Adverse behavioral reactions attributed to triazolam in the Food and Drug Administration's Spontaneous Reporting System." Arch Intern Med 151 (1991): 2003-8</p><p id="ref_8">8. Schogt B, Conn D "Paranoid symptoms associated with triazolam." Can J Psychiatry 30 (1985): 462-3</p><p id="ref_9">9. Schneider LS, Syapin PJ, Pawluczyk S "Seizures following triazolam withdrawal despite benzodiazepine treatment." J Clin Psychiatry 48 (1987): 418-9</p><p id="ref_10">10. Heritch AJ, Capwell R, Roy-Byrne PP "A case of psychosis and delirium following withdrawal from triazolam." J Clin Psychiatry 48 (1987): 168-9</p><p id="ref_11">11. Rush CR, Higgins ST, Hughes JR, Bickel WK "A comparison of the acute behavioral effects of triazolam and temazepam in normal volunteers." Psychopharmacology (Berl) 112 (1993): 407-14</p><p id="ref_12">12. Weilburg JB, Sachs G, Falk WE "Triazolam-induced brief episodes of secondary mania in a depressed patient." J Clin Psychiatry 48 (1987): 492-3</p><p id="ref_13">13. Sullivan RJ, Jr "Respiratory depression requiring ventilatory support following 0.5 mg of triazolam." J Am Geriatr Soc 37 (1989): 450-2</p><p id="ref_14">14. Berry RB, Kouchi K, Bower J, Prosise G, Light RW "Triazolam in patients with obstructive sleep apnea." Am J Respir Crit Care Med 151 (1995): 450-4</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Halcion (triazolam)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>28 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: benzodiazepines</li>
<li>FDA Alerts (2)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Halcion &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Insomnia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to triazolam: oral tablet</i></p><h3>General</h3><p>The most commonly reported side effects included drowsiness/sedation, dizziness/lightheadedness, headache, and ataxia.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Sedation (up to 19.4%), drowsiness (up to 14%)</p><p><b>Common</b> (1% to 10%): Anterograde amnesia with appropriate/inappropriate behavior, ataxia, concentration difficulty, coordination disorders/impaired coordination, dizziness, headache, impaired equilibrium, lethargy, lightheadedness, memory impairment</p><p><b>Rare</b> (0.01% to 0.1%): Dysesthesia, paresthesia, taste alterations</p><p><b>Frequency not reported</b>: Amnestic symptoms, clouding of consciousness/altered state of consciousness, dysarthria, dystonia, grogginess, slurred speech, somnambulism, somnolence, syncope<sup>[Ref]</sup></p><p>Complex behaviors, such as "sleep-driving", other behaviors such as preparing and eating food, making phone calls, or having sex, with amnesia for these events, have been reported at therapeutic doses with this medicine.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): WBC/high power field (HPF) in urinalysis (up to 11.3%)</p><p><b>Common</b> (1% to 10%): Albuminuria, red blood cells/HPF in urinalysis</p><p><b>Frequency not reported</b>: Bladder trouble, incontinence, menstrual irregularities, urinary retention<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Low eosinophil count (up to 10.2%)</p><p><b>Common</b> (1% to 10%): High eosinophil count, low monocyte count, low/high basophil count, low/high lymphocyte count, low/high neutrophil count, low/high WBC count</p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): High bilirubin, increased alkaline phosphatase, low/high creatinine</p><p><b>Frequency not reported</b>: Anorexia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Rebound insomnia (a worsening of sleep following cessation of therapy) has been observed and has sometimes been reported to occur in association with increased daytime anxiety.</p><p></p><p>Withdrawal symptoms have included agitation, restlessness, anxiety, insomnia, psychosis, delirium, convulsions, tremor, abdominal cramps, blurred vision, vomiting, and sweating.</p><p></p><p>Worsening of insomnia, depression, or the emergence of new thinking or behavior abnormalities, including suicidal thinking, have emerged during treatment with sedative-hypnotic drugs, including this drug.  The frequency and extent to which this drug is associated with adverse behavioral effects is controversial.</p><p></p><p>One study based on the postmarketing surveillance Spontaneous Reporting System of the FDA has suggested that adverse behavioral reactions have been reported 22 to 99 times more frequently in association with triazolam (the active ingredient contained in Halcion) therapy than with temazepam therapy for insomnia.  An increased frequency of adverse behavioral effects was noted to occur most frequently in elderly patients and at higher doses of this drug.  The methodology of this study, however, has been questioned on the grounds that spontaneous reports of adverse effects do not necessarily correlate with the incidence of adverse effects.</p><p></p><p>Other studies and reports have concluded that little evidence exists to support the contention that this drug is associated with a greater risk of adverse behavioral effects than other benzodiazepines (including temazepam).<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Anxiety, nervousness</p><p><b>Uncommon</b> (0.1% to 1%): Confusional states, depression, euphoria</p><p><b>Rare</b> (0.01% to 0.1%): Dreaming, insomnia, nightmares</p><p><b>Frequency not reported</b>: Abnormal behavior, abnormal dreams, abuse, acute rage, addiction, aggressiveness/aggression, agitation, agitational state, bizarre behavior, changes in libido, delusions, depersonalization, derealization, disorientation, disorientation in time/place, excitation, hallucinations, inappropriate behavior, irritability, libido disorder, mania, other adverse behavioral effects, paranoia, restlessness, sleep disorder/sleep disturbances, stimulation<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomiting</p><p><b>Rare</b> (0.01% to 0.1%): Constipation, diarrhea, dry mouth</p><p><b>Frequency not reported</b>: Abdominal distress, burning tongue, glossitis, stomatitis, tongue discomfort<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Tiredness</p><p><b>Uncommon</b> (0.1% to 1%): Pain</p><p><b>Rare</b> (0.01% to 0.1%): Tinnitus, weakness</p><p><b>Frequency not reported</b>: Falling, fatigue, paradoxical reactions<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): High AST levels</p><p><b>Rare</b> (0.01% to 0.1%): Death (from hepatic failure)</p><p><b>Frequency not reported</b>: Jaundice<sup>[Ref]</sup></p><p>Death from hepatic failure has been reported in a patient also receiving diuretic drugs.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Pruritus, skin rash</p><p><b>Rare</b> (0.01% to 0.1%): Dermatitis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Palpitations, tachycardia</p><p><b>Frequency not reported</b>: Chest pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Uncommon</b> (0.1% to 1%): Hiccups</p><p><b>Rare</b> (0.01% to 0.1%): Congestion<sup>[Ref]</sup></p><p>One study of patients with obstructive sleep apnea has suggested that this drug may increase the maximum apnea duration and lower the minimum oxygen saturation of apneic patients.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Cramps</p><p><b>Frequency not reported</b>: Aching limbs, backache, increased muscle spasticity<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Visual disturbances</p><p><b>Frequency not reported</b>: Blepharitis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (0.01% to 0.1%): Allergy</p><p><b>Postmarketing reports</b>: Anaphylactic shock, anaphylactoid reaction, allergic edema, angioneurotic edema, hypersensitivity reaction<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_3">3. Rothschild AJ "Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: a review of the literature." J Clin Psychiatry 53 (1992): 69-79</p><p id="ref_4">4. Morris HH, 3d  Estes ML "Traveler's amnesia. Transient global amnesia secondary to triazolam." JAMA 258 (1987): 945-6</p><p id="ref_5">5. Patterson WM "Triazolam withdrawal." J Clin Psychiatry 49 (1988): 369</p><p id="ref_6">6. Andreadis NA, Schirmer RG "Use of spontaneous reporting system data." Arch Intern Med 152 (1992): 1527-9</p><p id="ref_7">7. Wysowski DK, Barash D "Adverse behavioral reactions attributed to triazolam in the Food and Drug Administration's Spontaneous Reporting System." Arch Intern Med 151 (1991): 2003-8</p><p id="ref_8">8. Schogt B, Conn D "Paranoid symptoms associated with triazolam." Can J Psychiatry 30 (1985): 462-3</p><p id="ref_9">9. Schneider LS, Syapin PJ, Pawluczyk S "Seizures following triazolam withdrawal despite benzodiazepine treatment." J Clin Psychiatry 48 (1987): 418-9</p><p id="ref_10">10. Heritch AJ, Capwell R, Roy-Byrne PP "A case of psychosis and delirium following withdrawal from triazolam." J Clin Psychiatry 48 (1987): 168-9</p><p id="ref_11">11. Rush CR, Higgins ST, Hughes JR, Bickel WK "A comparison of the acute behavioral effects of triazolam and temazepam in normal volunteers." Psychopharmacology (Berl) 112 (1993): 407-14</p><p id="ref_12">12. Weilburg JB, Sachs G, Falk WE "Triazolam-induced brief episodes of secondary mania in a depressed patient." J Clin Psychiatry 48 (1987): 492-3</p><p id="ref_13">13. Sullivan RJ, Jr "Respiratory depression requiring ventilatory support following 0.5 mg of triazolam." J Am Geriatr Soc 37 (1989): 450-2</p><p id="ref_14">14. Berry RB, Kouchi K, Bower J, Prosise G, Light RW "Triazolam in patients with obstructive sleep apnea." Am J Respir Crit Care Med 151 (1995): 450-4</p><h2>More about Halcion (triazolam)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>28 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: benzodiazepines</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Halcion &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Insomnia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>